MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinsonism"

  • 2016 International Congress

    Prevalence of Parkinson’s disease and myotonic dystrophy in the nomadic population: Mongolian study

    T. Sosorburam, B. Samdan, J. Amar (Ulan-Bator, Mongolia)

    Objective: To determine the prevalence of Parkinson's disease (PD) and Myotonic Dystrophy (MD) in the isolated people, where a study never been conducted before regarding…
  • 2016 International Congress

    Ethnic differences in rates of Parkinson’s in New Zealand: A nation-wide prevalence and incidence study

    T.L. Pitcher, D.J. Myall, M.R. MacAskill, J.F. Pearson, C.J. Lacey, J.C. Dalrymple-Alford, T.J. Anderson (Christchurch, New Zealand)

    Objective: To estimate the prevalence and incidence of Parkinson's in New Zealand and to investigate if these measures differ between the major ethnic groups represented…
  • 2016 International Congress

    Effectiveness of occupational therapy multi-domain group therapy program for Parkinson’s disease

    R.K.M. Wong, D.S.W. Tsang, C.K.Y. Lau, A.Y.Y. Chan, D.T.M. Chan, X. Zhu, W. Poon, V.C.T. Mok (Hong Kong, Hong Kong)

    Objective: This pilot study investigated the effectiveness of an Occupational Therapy (OT) multi-domain group program on preventing fall, improving non-motor symptoms & reducing carers' stress…
  • 2016 International Congress

    Predictors of clinically meaningful change in PDQ-39 in Parkinson’s disease

    T. Simuni, S. Wu, Y. He, C. Marras, T. Davis, E. Nelson, F. Cubillos, P. Schmidt, On behalf of the NPF QII Investigators (Chicago, IL, USA)

    Objective: To determine predictors of a clinically meaningful change of HRQL of patients with PD. Background: There is limited literature on the baseline and longitudinal…
  • 2016 International Congress

    Potential advantages of high resolution lead designs for deep brain stimulation

    J. Wu, M. Astrom, G. Molnar (Minneapolis, MN, USA)

    Objective: The aim of this study is to summarize potential stimulation and sensing advantages of high resolution DBS leads. Background: Deep brain stimulation (DBS) is…
  • 2016 International Congress

    Efficacy and safety of a L-dopa delivery and monitoring medical device

    Y.G. Tirat-Gefen (Fairfax, VA, USA)

    Objective: The objective of this study is to evaluate algorithms in a medical device for l-dopa delivery and monitoring. This wearable medical device will measure…
  • 2016 International Congress

    Familial Parkinson’s disease in Ireland

    D.A. Olszewska, A. McCarthy, B. Magennis, O. Ross, T. Lynch (Dublin, Ireland)

    Objective: To study the phenotype and subtypes of familial Parkinson's disease (PD) in Ireland, establish the genetic background in a cohort of Irish PD patients…
  • 2016 International Congress

    SMPD1 mutations, acid-sphingomyelinase activity and α-synuclein accumulation in Parkinson’s disease

    Z. Gan-Or, V. Mallett, O. Tavassoly, Y. Dauvilliers, C. Leblond, A. Ambalavanan, S. Laurent, S. Strong, D. Spiegelman, A. Dionne-Laporte, C. Liong, O. Levy, S. Fahn, C. Waters, P. Mazzoni, S. Kuo, W. Chung, B. Ford, K. Marder, U. Kang, P. Wolf, P. Oliva, X. Zhang, L. Clark, P. Dion, E. Fon, N. Dupre, G. Rouleau, R. Alcalay (Montreal, Canada)

    Objective: To study the effects of SMPD1 (sphingomyelin phosphodiesterase-1 gene) variants and acid-sphingomyelinase (ASMase) activity on Parkinson's disease (PD), and the effect of SMPD1 knockdown…
  • 2016 International Congress

    Relationships of cognitive functions and psychiatric symptoms with motor phenotypes in patients with untreated early-stage Parkinson’s disease

    H. Terashi, Y. Ishimura, T. Taguchi, H. Mitoma, H. Aizawa (Tokyo, Japan)

    Objective: It has been shown that the clinical types of Parkinson's disease (PD) based on motor symptoms include motor phenotypes of postural instability and gait…
  • 2016 International Congress

    Drp1 inhibition amelioratesα-synuclein-mediated neurodegeneration in rats

    S. Bido, L. Arcuri, M. Helly, R. Fan, K. Tieu, E. Bezard (Bordeaux, France)

    Objective: To provide new insights on the relationships occurring between mitochondria physiology and α-synuclein (α-syn) accumulation in an animal model of progressive neurodegeneration. Background: In…
  • « Previous Page
  • 1
  • …
  • 356
  • 357
  • 358
  • 359
  • 360
  • …
  • 405
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley